Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens

被引：0
|
作者：
Sarah M. Kashanian
Noa G. Holtzman
Ciera L. Patzke
Jonathan Cornu
Alison Duffy
Madhurima Koka
Sandrine Niyongere
Vu H. Duong
Maria R. Baer
Jummai Apata
Farin Kamangar
Ashkan Emadi
机构：
[1] University of Maryland School of Medicine,Department of Medicine
[2] National Cancer Institute,Immune Deficiency Cellular Therapy Program, Center for Cancer Research
[3] National Institutes of Health,Greenebaum Comprehensive Cancer Center
[4] University of Maryland School of Medicine,Department of Pharmacy
[5] University of Maryland Medical Center,Department of Pathology
[6] University of Maryland School of Pharmacy,Center for Urban Health Disparities Research and Innovation
[7] University of Maryland School of Medicine,Department of Biology, School of Computer, Mathematical, and Natural Sciences
[8] Morgan State University,Department of Pharmacology
[9] Morgan State University,undefined
[10] University of Maryland School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
Acute lymphoblastic leukemia; Pegylated-asparaginase; Pegaspargase; ALL; Venous thromboembolism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：817 / 826
页数：9
相关论文
共 29 条
  • [1] Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens
    Kashanian, Sarah M.
    Holtzman, Noa G.
    Patzke, Ciera L.
    Cornu, Jonathan
    Duffy, Alison
    Koka, Madhurima
    Niyongere, Sandrine
    Duong, Vu H.
    Baer, Maria R.
    Apata, Jummai
    Kamangar, Farin
    Emadi, Ashkan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (06) : 817 - 826
  • [2] Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia
    Chen, Jason
    Ngo, Dat
    Aldoss, Ibrahim
    Shayani, Sepideh
    Tsai, Ni-Chun
    Pullarkat, Vinod
    LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1187 - 1192
  • [3] Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin
    Elliott, MA
    Wolf, RC
    Hook, CC
    Pruthi, RK
    Heit, JA
    Letendre, LL
    Tefferi, A
    Kaufmann, SH
    Mesa, RA
    Litzow, MR
    LEUKEMIA & LYMPHOMA, 2004, 45 (08) : 1545 - 1549
  • [4] Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia
    MH Woo
    LJ Hak
    MC Storm
    WE Evans
    JT Sandlund
    GK Rivera
    B Wang
    C-H Pui
    MV Relling
    Leukemia, 1998, 12 : 1527 - 1533
  • [5] PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability
    Verma, Anupam
    Chen, Karin
    Bender, Cynthia
    Gorney, Nathan
    Leonard, Whitney
    Barnette, Phillip
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2019, 36 (05) : 277 - 286
  • [6] Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis
    Klaassen, Irene L. M.
    Lauw, Mandy N.
    Fiocco, Marta
    van der Sluis, Inge M.
    Pieters, Rob
    Middeldorp, Saskia
    van de Wetering, Marianne D.
    de Groot-Kruseman, Hester A.
    van Ommen, C. Heleen
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (02) : 234 - 241
  • [7] Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival
    Ku, Grace H.
    White, Richard H.
    Chew, Helen K.
    Harvey, Danielle J.
    Zhou, Hong
    Wun, Ted
    BLOOD, 2009, 113 (17) : 3911 - 3917
  • [8] A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native E. coli asparaginase in children with acute lymphoblastic leukemia
    Al, Isik Odaman
    Ozdemir, Nihal
    Ersoy, Gizem Zengin
    Bayram, Cengiz
    Cilengiroglu, Ozgul Vupa
    Arslantas, Esra
    Uysalol, Ezgi Pasli
    Aycicek, Ali
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (06) : 1454 - 1460
  • [9] Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia
    Mateos, M. K.
    Trahair, T. N.
    Mayoh, C.
    Barbaro, P. M.
    Sutton, R.
    Revesz, T.
    Barbaric, D.
    Giles, J. E.
    Alvaro, F.
    Mechinaud, F.
    Catchpoole, D.
    Kotecha, R. S.
    Dalla-Pozza, L.
    Quinn, C. J.
    MacGregor, S.
    Chenevix-Trench, G.
    Marshall, G. M.
    THROMBOSIS RESEARCH, 2019, 178 : 132 - 138
  • [10] Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study
    Liu, Wen-jian
    Wang, Hua
    Wang, Wei-da
    Zhu, Meng-yuan
    Liu, Cheng-cheng
    Wang, Jing-hua
    Lu, Yue
    SCIENTIFIC REPORTS, 2016, 6
123